|   |   |                                                                                        |
|--------|--------|---------------------------------------------------------------------------------------------|
| þ |   | Quarterly      report under Section 13 or 15(d) of the Securities Exchange Act of      1934 |

|   |   |                                                                  |
|--------|--------|-----------------------------------------------------------------------|
| o      |   | Transition      report under Section 13 or 15(d) of the Exchange  Act |

|                                                                          |   |                                                    |
|-------------------------------------------------------------------------------|--------|---------------------------------------------------------|
| Nevada(State      or other jurisdiction ofincorporation      or organization) |   | 88-0380546(I.R.S.      EmployerIdentification      No.) |

| Large Accelerated      filer   o                                                                 | Accelerated      Filer                             o |
|------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                       |                                                                                                                                                                                                  |
| Non-Accelerated      Filer     ̈(Do not check if a smaller reporting      company) | Smaller Reporting      Company          þ                                                                                                           |

----

|                                                                                                                                                                                                                                               |   |   |   |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|
|                                                                                                                                                                                                                                               |   | Page   |
| Part I. Financial      Information                                                                                                                                                                                                                 |   |   | 1      |   |
|                                                                                                                                                                                                                                               |   |   |   |   |
| Item 1: Financial Statements      (Unaudited)                                                                                                                                                                                                      |   |   | 1      |   |
|                                                                                                                                                                                                                                               |   |   |   |   |
| Condensed Consolidated      Balance Sheets at April 30, 2010 (Unaudited) and October 31,      2009                                                                                                                                                 |   |   | 1      |   |
|                                                                                                                                                                                                                                               |   |   |   |   |
| Condensed Consolidated      Statements of Operations (Unaudited) for the Three      and Six Months ended April      30, 2010 and 2009 (Unaudited) and      cumulative from November 20, 1997 (Date of Inception) to April 30,      2010  |   |   | 2      |   |
|                                                                                                                                                                                                                                               |   |   |   |   |
| Condensed Consolidated      Statement of Changes in Stockholders’ Equity (Unaudited) for the Six      Months ended April 30, 2010                                                                                                            |   |   | 3      |   |
|                                                                                                                                                                                                                                               |   |   |   |   |
| Condensed Consolidated      Statements of Cash Flows (Unaudited)      for the Six Months ended April 30, 2010 and 2009 and      cumulative from November 20, 1997 (Date of Inception) to April 30,      2010                                       |   |   | 4      |   |
|                                                                                                                                                                                                                                               |   |   |   |   |
| Notes to Condensed      Consolidated Financial Statements at April 30, 2010 (Unaudited)                                                                                                                                                       |   |   | 5-15   |   |
|                                                                                                                                                                                                                                               |   |   |   |   |
| Item 2: Management’s Discussion      and Analysis                                                                                                                                                                                            |   |   | 15-18  |   |
|                                                                                                                                                                                                                                               |   |   |   |   |
| Item 3: Quantitative and      Qualitative Disclosures About Market Risk                                                                                                                                                                            |   |   | 18     |   |
|                                                                                                                                                                                                                                               |   |   |   |   |
| Item 4: Controls and Procedures                                                                                                                                                                                                                    |   |   | 18     |   |

----

| Part II. Other      Information                                          |   |   | 19     |   |
|--------------------------------------------------------------------------|--------|--------|--------|--------|
|                                                                     |   |   |   |   |
| Item 1: Legal      Proceedings                                           |   |   | 19     |   |
|                                                                     |   |   |   |   |
| Item 1A: Risk      Factors                                               |   |   | 19     |   |
|                                                                     |   |   |   |   |
| Item 2: Unregistered Sales of      Equity Securities and Use of Proceeds |   |   | 19     |   |
|                                                                     |   |   |   |   |
| Item 3: Defaults Upon Senior      Securities                             |   |   | 19     |   |
|                                                                     |   |   |   |   |
| Item 4: Removed and      Reserved                                        |   |   | 19     |   |
|                                                                     |   |   |   |   |
| Item 5: Other      Information                                           |   |   | 19     |   |
|                                                                     |   |   |   |   |
| Item 6:      Exhibits                                                    |   |   | 19     |   |
|                                                                     |   |   |   |   |
| Signatures                                                               |   |   | 20     |   |
|                                                                     |   |   |   |   |
| EX-31.1:      CERTIFICATION                                              |
| EX-31.2:      CERTIFICATION                                              |
| EX-32.1:      CERTIFICATIONS                                             |

----

CardioGenics Holdings Inc.

----

PART I.  FINANCIAL INFORMATION

Item 1.  Financial Statements (Unaudited)

|                                                                                               |   | April      30, |        |   | October      31, |    |
|----------------------------------------------------------------------------------------------------|--------|----------------|-------------|--------|------------------|---------|
|                                                                                               |   | 2010           |        |   | 2009             |    |
| Assets                                                                                             |   | (Unaudited)    |        |   | (Note      2)    |    |
|                                                                                               |   |           |        |   |             |    |
| Current                                                                                            |   |           |        |   |             |    |
|   Cash      and Cash Equivalents                                                         |   | $              | 1,352,368   |   |             | $       | 2,388,516 |   |
|   Deposits      and Prepaid Expenses                                                     |   |           | 50,197      |   |             |    | 11,996 |   |
|   Refundable      Taxes Receivable                                                       |   |           | 9,357       |   |             |    | 14,878 |   |
|   Government      Grants and Investment Tax Credits Receivable                           |   |           | 187,753     |   |             |    | 175,554 |   |
|                                                                                               |   |           | 1,599,675   |   |             |    | 2,590,944 |   |
|                                                                                               |   |           |        |   |             |    |   |   |
|                                                                                               |   |           |        |   |             |    |   |   |
|   Property and      Equipment, net                                                       |   |           | 39,991      |   |             |    | 54,338 |   |
|   Patents,      net                                                                      |   |           | 250,229     |   |             |    | 241,980 |   |
|                                                                                               |   |           | 290,220     |   |             |    | 296,318 |   |
|  Total      assets                                                                            |   | $              | 1,889,895   |   |             | $       | 2,887,262 |   |
|                                                                                               |   |           |        |   |             |    |   |   |
| Liabilities      and Stockholders' Equity                                                          |   |           |        |   |             |    |   |   |
|                                                                                               |   |           |        |   |             |    |   |   |
|                                                                                               |   |           |        |   |             |    |   |   |
| Current      Liabilities                                                                           |   |           |        |   |             |    |   |   |
|   Accounts      Payable and Accrued Expenses                                             |   | $              | 416,022     |   |             | $       | 651,037 |   |
|   Due      to Director                                                                   |   |           | 60,465      |   |             |    | 147,102 |   |
|   Debentures      Payable                                                                |   | ▬        |        |   |             | 25,000  |   |
|   Liabilities      of Discontinued Operations                                            |   | ▬        |        |   |             | 100,000 |   |
|                                                                                               |   |           | 476,487     |   |             |    | 923,139 |   |
|                                                                                               |   |           |        |   |             |    |   |   |
| Mandatorily      redeemable Class B common stock; par value $.00001 per    share:                  |   |           |        |   |             |    |   |   |
|   400,000      shares designated as series 2; 381,749 shares issued and      outstanding |   |           | 4           |   |             |    | 4 |   |
|   40,000      shares designated as series 3; 21,500 shares issued and      outstanding   |   | ▬        |        |   | ▬          |    |
|                                                                                               |   |           | 4           |   |             |    | 4 |   |
|                                                                                               |   |           |        |   |             |    |   |   |
| Commitments      and contingencies                                                                 |   |           |        |   |             |    |   |   |
| Stockholders'      Equity                                                                          |   |           |        |   |             |    |   |   |
| Preferred      stock; par value $.0001 per share,                                                  |   |           |        |   |             |    |   |   |
|   50,000,000      shares authorized, none issued                                         |   | ▬        |        |   | ▬          |    |
| Common      stock; par value $.00001 per share;                                                    |   |           |        |   |             |    |   |   |
|   650,000,000      shares authorized,                                                    |   |           |        |   |             |    |   |   |
|   245,554,164      and 217,671,011 common shares and                                     |   |           |        |   |             |    |   |   |
|   250,642,262      and 276,655,415 exchangeable shares issued and                        |   |           |        |   |             |    |   |   |
|   outstanding      as at April 30, 2010 and October 31, 2009 respectively                |   |           | 4,963       |   |             |    | 4,943 |   |
|                                                                                               |   |           |        |   |             |    |   |   |
| Additional      paid-in capital                                                                    |   |           | 35,700,504  |   |             |    | 35,539,274 |   |
|                                                                                               |   |           |        |   |             |    |   |   |
| Deficit      accumulated during development stage                                                  |   |           | (34,082,980 | )      |             |    | (33,260,283 | ) |
|                                                                                               |   |           |        |   |             |    |   |   |
| Accumulated      other comprehensive loss                                                          |   |           | (203,077    | )      |             |    | (319,815 | ) |
|                                                                                               |   |           |        |   |             |    |   |   |
| Total      CardioGenics Holdings Inc. stockholders' equity                                         |   |           | 1,419,410   |   |             |    | 1,964,119 |   |
| Non-controlling      interest                                                                      |   |           | (6,006      | )      |             | ▬ |   |
| Total      equity                                                                                  |   |           | 1,413,404   |   |             |    | 1,964,119 |   |
| Total      liabilities and stockholders' equity                                                    |   | $              | 1,889,895   |   |             | $       | 2,887,262 |   |

----

CardioGenics Holdings Inc.

----

|                                                                                                               |   |                            |        |   |                          |    |        |               |    | Cumulative    |        |
|--------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|-------------|--------|-------------------------------|---------|-------------|--------------------|---------|---------------|-------------|
|                                                                                                               |   |                            |        |   |                          |    |        |               |    | From          |        |
|                                                                                                               |   |                            |        |   |                          |    |        |               |    | November      |        |
|                                                                                                               |   |                            |        |   |                          |    |        |               |    | 20,      1997 |        |
|                                                                                                               |   |                            |        |   |                          |    |        |               |    | (Date      of |        |
|                                                                                                               |   | For      the three months Ended |        |   | For      the six months Ended |    |        | Inception)      to |    |
|                                                                                                               |   | April      30,                  |        |   | April      30,                |    |        | April      30,     |    |
|                                                                                                               |   | 2010                            |        |   | 2009                          |    |        | 2010               |    |          | 2009        |   |   | 2010 |   |
|                                                                                                               |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |
| Operating      Expenses                                                                                            |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |
|   Amortization      of Property and Equipment                                                            |   | $                               | 7,256       |   |                          | $       | 6,074       |               |    | $             | 14,347      |   |   | $ | 12,222 |   |   | $ | 174,455 |   |
|   Amortization      of Patent Application Costs                                                          |   |                            | 1,020       |   |                          | ▬ |        |               |    | 2,016         |        |   | ▬ |   |   |   | 6,197 |   |
|   Write-off      of Patent Application Costs                                                             |   | ▬                         |        |   | ▬                       |    |        | ▬            |    |          | ▬     |   |   |   | 53,731 |   |
|   General      and Administrative                                                                        |   |                            | 158,168     |   |                          |    | 31,492      |               |    |          | 449,622     |   |   |   | 56,035 |   |   |   | 3,478,844 |   |
|   Write-off      of Goodwill                                                                             |   | ▬                         |        |   | ▬                       |    |        | ▬            |    |          | ▬     |   |   |   | 12,780,214 |   |
|   Research      and Product Development, Net                                                             |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |   |   |   |   |
|     of      Investment Tax Credits                                                             |   |                            | 179,875     |   |                          |    | 39,548      |               |    |          | 312,685     |   |   |   | 71,042 |   |   |   | 2,908,401 |   |
|   Total      operating expenses and operating loss                                                       |   |                            | 346,319     |   |                          |    | 77,114      |               |    |          | 778,670     |   |   |   | 139,299 |   |   |   | 19,401,842 |   |
|                                                                                                               |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |   |   |   |   |
| Other      Expenses (Income)                                                                                       |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |   |   |   |   |
|   Interest      Expense and Bank Charges (Net)                                                           |   |                            | 3,171       |   |                          |    | 56,494      |               |    |          | 521         |   |   |   | 117,258 |   |   |   | 2,086,856 |   |
|   Loss      on Change in Value of Derivative Liability                                                   |   | ▬                         |        |   | ▬                       |    |        | ▬            |    |          | ▬     |   |   |   | 12,421,023 |   |
|   Loss      on Foreign Exchange Transactions                                                             |   |                            | 83,043      |   |                          |    | 14,414      |               |    |          | 102,208     |   |   |   | 14,414 |   |   |   | 116,554 |   |
|                                                                                                               |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |   |   |   |   |
|   Total      other expenses (income)                                                                     |   |                            | 86,214      |   |                          |    | 70,908      |               |    |          | 102,729     |   |   |   | 131,672 |   |   |   | 14,624,433 |   |
|                                                                                                               |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |   |   |   |   |
| Loss      from Continuing Operations                                                                               |   |                            | (432,533    | )      |                          |    | (148,022    | )                  |    |          | (881,399    | ) |   |   | (270,971 | ) |   |   | (34,026,275 | ) |
|                                                                                                               |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |   |   |   |   |
| Discontinued      Operations                                                                                       |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |   |   |   |   |
|   Gain  on      Sale of Subsidiary                                                             |   |                            | 90,051      |   |                          | ▬ |        |               |    | 90,051        |        |   | ▬ |   |   |   | 90,051 |   |
|   Loss      from Discontinued Operations                                                                 |   | ▬                         |        |   | ▬                       |    |        |               | (37,355 | )             |        | ▬ |   |   |   | (152,762 | ) |
| Net      Loss                                                                                                      |   |                            | (342,482    | )      |                          |    | (148,022    | )                  |    |          | (828,703    | ) |   |   | (270,971 | ) |   |   | (34,088,986 | ) |
| Net      Loss attributed to non-controlling interest                                                               |   |                            | (2,482      | )      |                          | ▬ |        |               |    | (6,006        | )           |   | ▬ |   |   |   | (6,006 | ) |
| Net      Loss attributed to CardioGenics Holdings Inc.                                                             |   | $                               | (340,000    | )      |                          | $       | (148,022    | )                  |    | $             | (822,697    | ) |   | $ | (270,971 | ) |   | $ | (34,082,980 | ) |
|                                                                                                               |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |   |   |   |   |
| Basic      and Fully Diluted Net Loss per CommonShare      attributable to CardioGenics Holdings Inc. Shareholders |   | $                               | (0.00       | )      |                          | $       | (0.00       | )                  |    | $             | (0.00       | ) |   | $ | (0.00 | ) |   |   |   |   |
|                                                                                                               |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |   |   |   |   |
| Weighted-average      shares of Common Stock outstanding                                                           |   |                            | 496,055,298 |   |                          |    | 292,089,211 |               |    |          | 495,201,671 |   |   |   | 289,094,335 |   |   |   |   |   |
|                                                                                                               |   |                            |        |   |                          |    |        |               |    |          |        |   |   |   |   |   |   |   |   |   |

----

CarioGenics Holdings Inc.

----

|                                                                                     |   |              |        |   |       |   |   | Deficit     |   |   |          |   |   |               |        |   |          |   |
|------------------------------------------------------------------------------------------|--------|-------------------|-------------|--------|------------|--------|--------|-------------|--------|--------|---------------|--------|--------|--------------------|-------------|--------|---------------|--------|
|                                                                                     |   |              |        |   |       |   |   | Accumulated |   |   |          |   |   |               |        |   |          |   |
|                                                                                     |   |              |        |   |       |   |   | During      |   |   | Accumulated   |   |   |               |        |   |          |   |
|                                                                                     |   |              |        |   | Additional |   |   | the         |   |   | Other         |   |   |               |        |   | Total         |   |
|                                                                                     |   | Common      Stock |        |   | Paid-in    |   |   | Development |   |   | Comprehensive |   |   | Noncontrolling     |        |   | Stockholders' |   |
|                                                                                     |   | Shares            |        |   | Amount     |   |   | Capital     |   |   | Stage         |   |   | Income      (Loss) |        |   | Interest      |   |   | Equity |   |
|                                                                                     |   |              |        |   |       |   |   |        |   |   |          |   |   |               |        |   |          |   |   |   |   |
| Balance      November 1, 2009                                                            |   |              | 494,326,426 |   |       | $      | 4,943  |        |   | $      | 35,539,274    |   |   | $                  | (33,260,283 | )      |          | $      | (319,815 | ) |   |   |   |   | $ | 1,964,119 |   |
| Issuance      of common shares in exchange for services rendered January 2010,      $.14 |   |              | 350,000     |   |       |   | 4      |        |   |   | 48,996        |   |   |               |        |   |          |   |   |   |   |   |   |   |   | 49,000 |   |
| Common      shares issued on exercise  of Warrants, February      2010         |   |              | 750,000     |   |       |   | 8      |        |   |   | 35,242        |   |   |               |        |   |          |   |   |   |   |   |   |   |   | 35,250 |   |
| Common      shares issued for cash, February 2010                                        |   |              | 770,000     |   |       |   | 8      |        |   |   | 76,992        |   |   |               |        |   |          |   |   |   |   |   |   |   |   | 77,000 |   |
| Net      loss attributable to noncontrolling interest                                    |   |              |        |   |       |   |   |        |   |   |          |   |   |               |        |   |          |   |   |   |   | $ | (6,006 | ) |   |   | (6,006 | ) |
| Comprehensive      Income (Loss)                                                         |   |              |        |   |       |   |   |        |   |   |          |   |   |               |        |   |          |   |   |   |   |   |   |   |   |   |   |   |
|   Net      Loss                                                                |   |              |        |   |       |   |   |        |   |   |          |   |   |               | (822,697    | )      |          |   |   |   |   |   |   |   |   |   | (822,697 | ) |
|   Other      Comprehensive Income (Loss)                                       |   |              |        |   |       |   |   |        |   |   |          |   |   |               |        |   |          |   |   |   |   |   |   |   |   |   |   |   |
|     Currency      Translation Adjustment                             |   |              |        |   |       |   |   |        |   |   |          |   |   |               |        |   |          |   | 116,738 |   |   |   |   |   |   |   | 116,738 |   |
|       Total      Comprehensive (Loss)                      |   |              |        |   |       |   |   |        |   |   |          |   |   |               |        |   |          |   |   |   |   |   |   |   |   |   | (705,959 | ) |
| Balance      at April 30, 2010                                                           |   |              | 496,196,426 |   |       | $      | 4,963  |        |   | $      | 35,700,504    |   |   | $                  | (34,082,980 | )      |          | $      | (203,077 | ) |   | $ | (6,006 | ) |   | $ | 1,413,404 |   |

----

CardioGenics Holdings Inc.

----

|                                                                                                     |   |                  |       |   |                     |    |     | Cumulative      from   |       |
|----------------------------------------------------------------------------------------------------------|--------|-----------------------|------------|--------|--------------------------|---------|----------|------------------------|------------|
|                                                                                                     |   |                  |       |   |                     |    |     | November      20, 1997 |       |
|                                                                                                     |   | Six      Months Ended |       |   | (Date      of Inception) |    |
|                                                                                                     |   | April      30         |       |   | To      April 30,        |    |
|                                                                                                     |   | 2010                  |       |   | 2009                     |    |     | 2010                   |       |
| Cash      flows from operating activities                                                                |   |                  |       |   |                     |    |     |                   |       |
|     Net      Loss for the Period                                                     |   | $                     | (828,703   | )      |                     | $       | (270,971 | )                      |       | $ | (34,088,986 | ) |
|     Adjustments      to reconcile net loss for the period to                         |   |                  |       |   |                     |    |     |                   |       |   |   |   |
|       net      cash used in operating activities                           |   |                  |       |   |                     |    |     |                   |       |   |   |   |
|       Amortization      of Property and Equipment                          |   |                  | 14,347     |   |                     |    | 12,222   |                   |       |   | 174,455 |   |
|       Amortization      of Patent Application Costs                        |   |                  | 2,016      |   |                     | ▬ |     |                   |       | 6,197 |   |
|       Write-off      of Patent Application Costs                           |   | ▬               |       |   | ▬                  |    |     |                   | 53,731     |   |
|       Write-off      of Goodwill                                           |   | ▬               |       |   | ▬                  |    |     |                   | 12,780,214 |   |
|       Amortization      of Deferred Debt Issuance Costs                    |   | ▬               |       |   | ▬                  |    |     |                   | 511,035    |   |
|       Loss      on Extinguishment of Debt                                  |   | ▬               |       |   | ▬                  |    |     |                   | 275,676    |   |
|       Loss      on Change in Value of Derivative Liability                 |   | ▬               |       |   | ▬                  |    |     |                   | 12,421,023 |   |
|       Interest      Accrued and Foreign Exchange Loss                      |   |                  |       |   |                     |    |     |                   |       |   |   |   |
|          on      Debt                                       |   | ▬               |       |   |                     | 74,292  |     |                   |       | 922,539 |   |
|       Unrealized      Foreign Currency Exchange Gains                      |   | ▬               |       |   |                     | 10,040  |     |                   |       | 25,092 |   |
|       Beneficial      Conversion Charge included in                        |   |                  |       |   |                     |    |     |                   |       |   |   |   |
|          Interest      Expense                              |   | ▬               |       |   | ▬                  |    |     |                   | 452,109    |   |
|       Common      Stock Issued as Employee or                              |   |                  |       |   |                     |    |     |                   |       |   |   |   |
|          Officer/Director      Compensation                 |   | ▬               |       |   | ▬                  |    |     |                   | 2,508,282  |   |
|       Common      Stock Issued for Services Rendered                       |   |                  | 49,000     |   |                     | ▬ |     |                   |       | 451,312 |   |
|       Stock      Options Issued for Services Rendered                      |   | ▬               |       |   | ▬                  |    |     |                   | 192,238    |   |
|       Stock      Options Issued to Directors and                           |   |                  |       |   |                     |    |     |                   |       |   |   |   |
|          Committee      Chairman                            |   | ▬               |       |   | ▬                  |    |     |                   | 54,582     |   |
|       Changes      in Operating Assets and Liabilities,                    |   |                  |       |   |                     |    |     |                   |       |   |   |   |
|          Net      of Acquisition                            |   |                  |       |   |                     |    |     |                   |       |   |   |   |
|         Deposits      and Prepaid Expenses                       |   |                  | (37,367    | )      |                     |    | 58       |                   |       |   | (48,574 | ) |
|         Refundable      Taxes Receivable                         |   |                  | 6,554      |   |                     |    | 5,652    |                   |       |   | (7,460 | ) |
|         Investment      Tax Credits Receivable                   |   | ▬               |       |   |                     | 104,208 |     |                   |       | (155,502 | ) |
|         Accounts      Payable and Accrued Expenses               |   |                  | (360,371   | )      |                     |    | 28,935   |                   |       |   | (377,232 | ) |
|         Advances                                                 |   | ▬               |       |   | ▬                  |    |     |                   | 131        |   |
|           Net      cash used in operating activities   |   |                  | (1,154,524 | )      |                     |    | (35,564  | )                      |       |   | (3,849,138 | ) |
|                                                                                                     |   |                  |       |   |                     |    |     |                   |       |   |   |   |
| Cash      flows from investing activities                                                                |   |                  |       |   |                     |    |     |                   |       |   |   |   |
|     Cash      Acquired from Acquisition                                              |   | ▬               |       |   | ▬                  |    |     |                   | 195,885    |   |
|     Purchase      of Property and Equipment                                          |   | ▬               |       |   |                     | (269    | )        |                   |       | (193,366 | ) |
|     Patent      Application Costs                                                    |   |                  | (10,265    | )      |                     |    | (419     | )                      |       |   | (269,980 | ) |
|         Net      cash used in investing activities               |   |                  | (10,265    | )      |                     |    | (688     | )                      |       |   | (267,461 | ) |
|                                                                                                     |   |                  |       |   |                     |    |     |                   |       |   |   |   |
| Cash      flows from financing activities                                                                |   |                  |       |   |                     |    |     |                   |       |   |   |   |
|     Due      to Director                                                             |   |                  | (96,860    | )      |                     |    | 10,537   |                   |       |   | 775,572 |   |
|     Issue      of Debentures                                                         |   | ▬               |       |   |                     | 371,333 |     |                   |       | 1,378,305 |   |
|     Issue      of Common Shares on Exercise of Stock options                         |   | ▬               |       |   |                     | 28      |     |                   |       | 31 |   |
|     Issue      of Common Shares on Exercise of Warrants                              |   |                  | 35,250     |   |                     | ▬ |     |                   |       | 35,250 |   |
|     Issue      of Common Shares for Cash                                             |   |                  | 77,000     |   |                     | ▬ |     |                   |       | 3,645,847 |   |
|     Redemption      of 10% Senior Convertible Debentures                             |   |                  | (25,000    | )      |                     |    | (369,972 | )                      |       |   | (394,972 | ) |
|         Net      cash provided by (used in) financing activities |   |                  | (9,610     | )      |                     |    | 11,926   |                   |       |   | 5,440,033 |   |
|                                                                                                     |   |                  |       |   |                     |    |     |                   |       |   |   |   |
| Effect      of foreign exchange on cash and cash equivalents                                             |   |                  | 138,251    |   |                     |    | 2,525    |                   |       |   | 28,934 |   |
| Cash      and Cash Equivalents                                                                           |   |                  |       |   |                     |    |     |                   |       |   |   |   |
| Increase      (decrease) in cash and cash equivalents                                                    |   |                  |       |   |                     |    |     |                   |       |   |   |   |
|     during      the period                                                           |   |                  | (1,036,148 | )      |                     |    | (21,801  | )                      |       |   | 1,352,368 |   |
|     Beginning      of Period                                                         |   |                  | 2,388,516  |   |                     |    | 253,873  |                   |       | ▬ |   |
|     End      of Period                                                               |   | $                     | 1,352,368  |   |                     | $       | 232,072  |                   |       | $ | 1,352,368 |   |

----

CardioGenics Holdings Inc.

----

| 1. | Nature      of Business |
|----|-------------------------|

| 2. | Basis      of Presentation |
|----|----------------------------|

----

| 3. | Summary of Significant      Accounting Policies. |
|----|--------------------------------------------------|

| (a)           | Research      and Development Costs |
|-----------------------------------|-------------------------------------|

| (b)           | Net      Loss Per Common Share |
|-----------------------------------|--------------------------------|

| (c)           | Use      of Estimates |
|-----------------------------------|-----------------------|

| (d)           | Discontinued      Operations |
|-----------------------------------|------------------------------|

| (e)           | Financial      Instruments |
|-----------------------------------|----------------------------|

| (f)           | Effects      of Recent Accounting Pronouncements |
|-----------------------------------|--------------------------------------------------|

----

| 4. | Acquisition |
|----|-------------|

----

|                                            |   |   |       |
|-------------------------------------------------|--------|--------|------------|
| Common      stock issued                        |   | $      | 11,573,536 |   |
| Acquisition      costs incurred                 |   |   | 342,880    |   |
| Fair      value of options and warrants assumed |   |   | 644,806    |   |
| Total      purchase price                       |   | $      | 12,561,222 |   |

| Cash                                           |   | $      | 195,885    |   |
|------------------------------------------------|--------|--------|------------|--------|
| Accounts      Payable                          |   |   | (386,177   | )      |
| Derivative      liability for warrants assumed |   |   | (28,700    | )      |
| Goodwill                                       |   |   | 12,780,214 |   |
| Total                                          |   | $      | 12,561,222 |   |

|                                                                                |   | Three      Months EndedApril      30, 2009 |               |   | Six      Months EndedApril      30, 2009 |   |
|-------------------------------------------------------------------------------------|--------|--------------------------------------------|--------------------|--------|------------------------------------------|--------|
|                                                                                |   |                                       |               |   |                                     |   |
| Revenues                                                                            |   | $                                          | 32,260             |   |                                     | $      | 73,913 |   |
| Net      Loss                                                                       |   | $                                          | (380,760           | )      |                                     | $      | (927,518 | ) |
| Weighted-average      shares ofCommon      stock outstanding:Basic      and diluted |   |                                       |   292,089,211 |   |                                     |   |   289,094,335 |   |
| Basic      and diluted net loss per common share                                    |   | $                                          | 0.00               |   |                                     | $      | 0.00 |   |

| 5. | Due      to Director |
|----|----------------------|

----

| 6. |   Income      Taxes |
|----|-------------------------------|

| 7. | Debentures      Payable |
|----|-------------------------|

|                                   |                                                                                   |   |
|----------------------------------------|----------------------------------------------------------------------------------------|--------|
|                                   | April      30,2010                                                                     |   | October      31,2009 |   |
|                                   |                                                                                   |   |   |   |
| 10%      Senior Convertible Debentures | $             ▬ |   | $ | 25,000 |   |

| 8. | Stock      Based Compensation |
|----|-------------------------------|

----

|                                      |    |    | Weighted   |   |
|-------------------------------------------|---------|---------|------------|--------|
|                                      |    |    | Average    |   |
|                                      |    |    | Exercise   |   |
|                                      | Options |    | Price      |   |
|                                      |    |    |       |   |
| Outstanding      - October 31, 2008       |    |    | 9,901,198  |   |   | $ | 0.02 |   |
| Granted                                   |    | ▬ |       |   | ▬ |   |
| Forfeited/expired                         |    |    | (4,191,400 | )      |   | $ | 0.06 |   |
| Exercised                                 |    |    | (5,709,798 | )      |   | $ | 0.05 |   |
| Assumed      upon JAG Media acquisition   |    |    | 2,750,000  |   |   | $ | 0.25 |   |
| Granted                                   |    |    | 300,000    |   |   | $ | 0.09 |   |
| Outstanding      – October 31, 2009 |    |    | 3,050,000  |   |   | $ | 0.23 |   |
| Granted                                   | ▬ |    | ▬    |   |
| Forfeited/Expired                         | ▬ |    | ▬    |   |
| Exercised                                 |    |    | ▬    |   |   |   | ▬ |   |
| Outstanding      – April 30, 2010   |    |    | 3,050,000  |   |   | $ | 0.23 |   |

| 9. | Stockholders’      Equity |
|----|---------------------------------|

|                                 |   | For      the Three Months EndedApril      30, |     |   | For      the Six Months EndedApril      30, |   |
|--------------------------------------|--------|-----------------------------------------------|----------|--------|---------------------------------------------|--------|
|                                 |   | 2010                                          |     |   | 2009                                        |   |   | 2010 |   |   | 2009 |   |
| Net      (Loss)                      |   | $                                             | (340,000 | )      |                                        | $      | (148,022 | ) |   | $ | (822,697 | ) |   | $ | (270,971 | ) |
| Currency      translation adjustment |   |                                          | 66,395   |   |                                        |   | (69,362 | ) |   |   | 116,738 |   |   |   | 10,040 |   |
| Comprehensive      (Loss)            |   | $                                             | (273,605 | )      |                                        | $      | (217,384 | ) |   | $ | (705,959 | ) |   | $ | (260,931 | ) |

----

|                                                                                                                                                                                                                                                            |               |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------|
|                                                                                                                                                                                                                                                            | April      30,2010 |   | October      31,2009 |   |
|                                                                                                                                                                                                                                                            |               |   |   |   |
| WarrantsIssued      to subscribers to the debenture financing of 2003 and its related      extension entitling the holder to purchase 1 common share of the Company      at an exercise price of $0.047 per common share up to and including July      31, 2012 | 20,468,082         |   | 21,218,082 |   |
|                                                                                                                                                                                                                                                            |               |   |   |   |
| Issued      to subscribers to the debenture financing of 2004 and its related      extension entitling the holder to purchase 1 common share in the Company      at an exercise price of $0.047 per common share up to and including July      31, 2012         | 10,436,586         |   | 10,436,586 |   |
|                                                                                                                                                                                                                                                            |               |   |   |   |
| Issued      to agents for the debenture financings of 2003 and 2004 entitling the      holder to  purchase 1 common share in the Company at an exercise      price of $0.047 per common share up to and including July 31,      2012                  | 2,084,174          |   | 2,084,174 |   |
|                                                                                                                                                                                                                                                            |               |   |   |   |
| Issued      to former employee entitling the holder to purchase 1 common share in the      company at an exercise price of $0.047 per common share up to and      including July 31, 2012                                                                       | 1,362,205          |   | 1,362,205 |   |
|                                                                                                                                                                                                                                                            |               |   |   |   |
| Issued      to Consultants July 31, 2009, entitling the holder to purchase 1 common      share of the company at an exercise price of $0.09 per share up to and      including July 31, 2012                                                                    | 1,047,850          |   | 1,047,850 |   |
|                                                                                                                                                                                                                                                            |               |   |   |   |
| Issued      to consultant August 1, 2009, entitling the holder to purchase 1 common      share in the company at an exercise price of $0.09 per common share up to      and including July 31, 2017                                                             | 2,870,848          |   | 2,870,848 |   |
|                                                                                                                                                                                                                                                            |               |   |   |   |
| Total      Warrants outstanding                                                                                                                                                                                                                                 | 38,269,745         |   | 39,019,745 |   |

----

| 10. | Standby      Equity Distribution Agreement |
|-----|--------------------------------------------|

----

|                                               |   | Six      Months EndedApril      30, 2010 |    |
|----------------------------------------------------|--------|------------------------------------------|---------|
|                                               |   | #      of shares                         |    |   | Amount |   |
|                                               |   |                                     |    |   |   |   |
| Issued      to third parties for services rendered |   |                                     | 350,000 |   |   | $ | 49,000 |   |
| Issued      on exercise of warrants                |   |                                     | 750,000 |   |   | $ | 35,250 |   |
| Issued      to unrelated third party for cash      |   |                                     | 770,000 |   |   | $ | 77,000 |   |

| 12. | Net      Loss per Share |
|-----|-------------------------|

|                                   |   | Three      Months EndedApril      30, |        |   | Six      Months EndedApril      30, |   |
|----------------------------------------|--------|---------------------------------------|-------------|--------|-------------------------------------|--------|
|                                   |   | 2010                                  |        |   | 2009                                |   |   | 2010 |   |   | 2009 |   |
|                                   |   |                                  |        |   |                                |   |   |   |   |   |   |   |
| Weighted-average      shares - basic   |   |                                  | 496,055,298 |   |                                |   | 292,089,211 |   |   |   | 495,201,671 |   |   |   | 289,094,335 |   |
| Effect      of dilutive securities     |   | ▬                               |        |   | ▬                             |   |   | ▬ |   |   | ▬ |   |
| Weighted-average      shares - diluted |   |                                  | 496,055,298 |   |                                |   | 292,089,211 |   |   |   | 495,201,671 |   |   |   | 289,094,335 |   |

| 13. | Commitments      and Contingent Liabilities |
|-----|---------------------------------------------|

| a)   | On      April 22, 2009, the Company was served with a statement of claim from a      former employee claiming compensation for wrongful dismissal and ancillary      causes of action including payment of monies in realization of his      investment in the Company, with an aggregate claim of      $514,000.  The Company considers all the claims to be without      any merit, has already delivered a statement of defense and intends to      vigorously defend the action.  If the matter eventually proceeds      to trial, the Company does not expect to be found liable on any ground or      for any cause of action. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| b)   | On      January 14, 2010, Flow Capital Advisors, Inc. (“Flow Capital”) filed      a lawsuit against JAG Media Holdings Inc. in the Circuit Court of the      17th      Judicial Circuit In and For Broward County Florida (Case No.      10001713).  Pursuant to this lawsuit, Flow Capital alleges that      JAG Media Holdings breached a Non-Circumvention Agreement it had entered      into with Flow Capital, dated January 1, 2004. JAG      Media Holdings has moved to dismiss the case because Flow Capital is not      registered to transact business in the state of Florida and is therefore      barred from maintaining the suit under applicable law. The motion is      pending. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14. | Supplemental      Disclosure of Cash Flow Information |
|-----|-------------------------------------------------------|

|                                  |   | For      the Six Months Ended |    |
|---------------------------------------|--------|-------------------------------|---------|
|                                  |   | April      30,                |    |
|                                  |   | 2010                          |    |   | 2009 |   |
|                                  |   |                          |    |   |   |   |
|                                  |   |                          |    |   |   |   |
| Cash      paid during the period for: |   |                          |    |   |   |   |
| Interest                              |   | $                             | 2,867   |   |   | $ | 886 |   |
|  Income      taxes               |   | $                             | ▬ |   |   | $ | ▬ |   |
|                                  |   |                          |    |   |   |   |   |   |

| 15. | Assets      and Liabilities from DiscontinuedOperations |
|-----|---------------------------------------------------------|

|                                                |   | 2010                                                                                                                                                          |   | 2009   |    |
|-----------------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|---------|
|                                                |   |                                                                                                                                                          |   |   |    |
| Liabilities                                         |   |                                                                                                                                                          |   |   |    |
|    Accounts      Payable             | $      |                          ▬ |   | $      | 100,000 |   |
| Total      Liabilities from Discontinued Operations | $      |                          ▬ |   | $      | 100,000 |   |

----

| 16. | Subsequent      Events |
|-----|------------------------|

Item 2.  Management’s Discussion andAnalysis

|                                                        |                 |   |    |   |          |   |    |   |   |
|-------------------------------------------------------------|----------------------|--------|---------|--------|---------------|--------|---------|--------|--------|
|                                                        | Six      Months      |   |    |   |
|                                                        | Ended      April 30, |   |    |   |
|                                                        | 2010                 |   | 2009    |   | $      Change |   |
|                                                        |                 |   |    |   |          |   |
| Operating      expenses:                                    |                 |   |    |   |          |   |    |   |   |
| Amortization      of property and equipment                 |                 | $      | 14,347  |   |          | $      | 12,222  |   |   | $ | 2,125 |   |
| Amortization      of patent application costs               |                 |   | 2,016   |   |          |   | -       |   |   |   | 2,016 |   |
| General      and administrative expenses                    |                 |   | 449,622 |   |          |   | 56,035  |   |   |   | 393,587 |   |
| Research      and production, net of investment tax credits |                 |   | 312,685 |   |          |   | 71,042  |   |   |   | 241,643 |   |
| Total      operating expenses and operating loss            |                 |   | 778,670 |   |          |   | 139,299 |   |   |   | 639,371 |   |
|                                                        |                 |   |    |   |          |   |    |   |   |   |   |   |
| Other      expenses (income):                               |                 |   |    |   |          |   |    |   |   |   |   |   |
| Interest      expense and bank charges, net                 |                 |   | 521     |   |          |   | 117,258 |   |   |   | (116,737 |  ) |
| Loss      on foreign exchange                               |                 |   | 102,208 |   |          |   | 14,414  |   |   |   | 87,794 |   |
| Gain      on sale of subsidiary                             |                 |   | (90,051 | )      |          |   | -       |   |   |   | (90,051 |  ) |
| Loss      on discontinued operation                         |                 |   | 37,355  |   |          |   | -       |   |   |   | 37,355 |   |
|                                                        |                 |   |    |   |          |   |    |   |   |   |   |   |
| Net      loss                                               |                 | $      | 828,703 |   |          | $      | 270,971 |   |   | $ | 557,732 |   |

----

|                                                        |                 |   |    |   |          |   |    |   |   |
|-------------------------------------------------------------|----------------------|--------|---------|--------|---------------|--------|---------|--------|--------|
|                                                        | Three      Months    |   |    |   |
|                                                        | Ended      April 30, |   |    |   |
|                                                        | 2010                 |   | 2009    |   | $      Change |   |
|                                                        |                 |   |    |   |          |   |
| Operating      expenses:                                    |                 |   |    |   |          |   |    |   |   |
| Amortization      of property and equipment                 |                 | $      | 7,256   |   |          | $      | 6,074   |   |   | $ | 1,182 |   |
| Amortization      of patent application costs               |                 |   | 1,020   |   |          |   | -       |   |   |   | 1,020 |   |
| General      and administrative expenses                    |                 |   | 158,168 |   |          |   | 31,492  |   |   |   | 126,676 |   |
| Research      and production, net of investment tax credits |                 |   | 179,875 |   |          |   | 39,548  |   |   |   | 140,327 |   |
| Total      operating expenses and operating loss            |                 |   | 346,319 |   |          |   | 77,114  |   |   |   | 269,205 |   |
|                                                        |                 |   |    |   |          |   |    |   |   |   |   |   |
| Other      expenses (income)                                |                 |   |    |   |          |   |    |   |   |   |   |   |
| Interest      expense and bank charges, net                 |                 |   | 3,171   |   |          |   | 56,494  |   |   |   | (53,323 |  ) |
| Loss      on foreign exchange                               |                 |   | 83,043  |   |          |   | 14,414  |   |   |   | 68,629 |   |
| Gain      on sale of subsidiary                             |                 |   | (90,051 | )      |          |   | -       |   |   |   | (90,051 |  ) |
|                                                        |                 |   |    |   |          |   |    |   |   |   |   |   |
| Net      loss                                               |                 | $      | 342,482 |   |          | $      | 148,022 |   |   | $ | 194,460 |   |
|                                                        |                 |   |    |   |          |   |    |   |   |   |   |   |

----

----

Item 3. Quantative andQualitative Disclosure About Market Risk

Item 4. Controls and Procedures

|  | •  | lack      of documented policies and procedures |
|--|---------------|-------------------------------------------------|

|   | • | there      is no effective separation of duties, which includes monitoring controls,      between the members of management |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------|

|   | • | lack      of resources to account for complex and unusual    transactions |
|--------|---------|---------------------------------------------------------------------------|

----

PART II. OTHER INFORMATION

Item 1. LegalProceedings

Item 1A. RiskFactors

| Date of      Exercise |   | Exercise      Price/Share |   |   | Shares      Exercised |   |    | Aggregate Exercise      Amount |   |
|-----------------------|--------|---------------------------|--------|--------|-----------------------|--------|---------|--------------------------------|--------|
| February 1,      2010 |   | $                         | 0.047  |   |                  |   | 750,000 |                           |   | $ | 35,250 |   |

Item 3. DefaultsUpon Senior Securities 

Item 4. (Removed andReserved)

Item 5. OtherInformation

Item 6.Exhibits

|  31.1 |   | Section      302 Certification of Chief Executive Officer.                                  |
|------------|--------|---------------------------------------------------------------------------------------------|
|       |   |                                                                                        |
|  31.2 |   | Section      302 Certification of Chief Financial Officer.                                  |
|       |   |                                                                                        |
|  32.1 |   | Section      906 Certification of Chief Executive Officer and Chief Financial      Officer. |

----

SIGNATURES

|                     | CARDIOGENICS      HOLDINGS INC. |                                            |
|--------------------------|---------------------------------|-------------------------------------------------|
|                     |                            |                                            |   |
| Date:      June 14, 2010 | By:                             | /s/ Yahia      Gawad                       |   |
|                     |                            | Name:      Yahia Gawad                          |   |
|                     |                            | Title:        Chief Executive Officer |   |
|                     |                            |                                            |   |

|                     |   |                                            |   |
|--------------------------|--------|-------------------------------------------------|--------|
| Date:      June 14, 2010 | By:    | /s/ James      Essex                       |   |
|                     |   | Name:      James Essex                          |   |
|                     |   | Title:        Chief Financial Officer |   |
|                     |   |                                            |   |

----

|   |   |                                                                                       |
|--------|--------|--------------------------------------------------------------------------------------------|
| 31.1   |   | Section      302 Certification of Chief Executive Officer                                  |
|   |   |                                                                                       |
| 31.2   |   | Section      302 Certification of Chief Financial Officer                                  |
|   |   |                                                                                       |
| 32.1   |   | Section      906 Certification of Chief Executive Officer and Chief Financial      Officer |

----